Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

NCT05983159 is registered in ClinicalTrials.gov with Murdoch Childrens Research Institute as lead sponsor.

NCT NCT05983159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)
Lead sponsor
Murdoch Childrens Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
September 13, 2024
Completion date
May 31, 2027
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

arteriovenous malformation (avm), arteriovenous malformations, cystic hygroma, fast-flow vascular malformation, kras g12c, kras g12d, lymphangioma, lymphatic malformation, lymphatic malformation, low flow, map2k1 gene mutation, pi3k gene mutation, pik3ca-related overgrowth spectrum, slow-flow vascular malformation, vascular anomalies, vascular anomaly, vascular malformations, venous malformation, venous malformation, low flow